Shimane Toshikazu, Mori Tomoaki, Ono Tomohiro, Kaburagi Aya, Monden Tetsuya, Furuya Ayako, Kamakazu Kiyoaki, Kobayashi Sei, Sanbe Takeyuki, Suzaki Harumi
Dept. of Otorhinolaryngology, Showa University, Fujigaoka Hospital.
Gan To Kagaku Ryoho. 2009 Dec;36(13):2561-4.
The development of reconstructive surgery and the use of free flaps have allowed for a larger dissection range even for advanced tongue cancer, resulting in an improvement of the prognosis. However, both the postoperative swallowing and masticatory function are still considered to have not yet reached a satisfactory level. Accordingly, our department has been administering concurrent chemoradiotherapy (CCRT) for advanced cancer to preserve the organ and the function; there are cases in which even comparatively small tumors are difficult to dissect due to the occurrence site. We have been treating these cases using CCRT as well. We herein report our results of 10 tongue cancer cases in which CCRT with S-1 and Nedaplatin (hereinafter, referred to as SN therapy) was administered in our department from April 2002 to October 2008. The complete response rate of the SN therapy was 60. 0% (6 of 10 examples). The 5-year disease-specific survival rates were 50. 0% for Stage II, 75. 0% for Stage III, and 75. 0% for Stage IV, respectively.
重建外科手术的发展以及游离皮瓣的应用，即使对于晚期舌癌也能实现更大范围的切除，从而改善了预后。然而，术后吞咽和咀嚼功能仍被认为尚未达到令人满意的水平。因此，我们科室一直对晚期癌症患者施行同步放化疗（CCRT）以保留器官和功能；存在一些病例，即使肿瘤相对较小，但由于发生部位的原因，也难以进行切除。我们也一直在使用CCRT治疗这些病例。在此，我们报告2002年4月至2008年10月期间在我们科室对10例舌癌患者施行S-1与奈达铂同步放化疗（以下简称SN疗法）的结果。SN疗法的完全缓解率为60.0%（10例中的6例）。II期、III期和IV期的5年疾病特异性生存率分别为50.0%、75.0%和75.0%。
